We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Higher Royalties From Partners Fuel HALO's Growth in H2 2025?
Read MoreHide Full Article
Key Takeaways
HALO's royalty revenues surged 52.3% in H1 2025 to $373.8 million on partnered drug growth.
First-half 2025 revenues jumped on higher royalties from Roche, J&J and argenx products.
HALO raised its 2025 revenue forecast to $1.28-$1.36 billion, driven by strong royalty momentum.
Halozyme Therapeutics (HALO - Free Report) has collaboration agreements with large pharma companies, which use its ENHANZE technology for the development of subcutaneous (SC) formulations of their various approved drugs. Halozyme now has eight marketed partnered drugs based on this technology, including the subcutaneous formulation of J&J’s (JNJ - Free Report) Darzalex and Roche’s (RHHBY - Free Report) Phesgo.
Per the agreements, these companies have been granted worldwide license rights to develop and commercialize their products using ENHANZE technology. These deals generate royalties on sales of marketed drugs, milestone payments and annual license fees, which comprise Halozyme’s top line.
Halozyme’s top line also comprises product sales, royalty payments from Roche for Phesgo and J&J for SC Darzalex as well as revenues under collaboration agreements related to its Enhanze technology with some large pharma companies. Total revenues in the first half of 2025 were driven by higher royalty payments from Roche for Phesgo and J&J for SC Darzalex (daratumumab), as well as argenx’s Vyvgart Hytrulo. Revenues from royalties rose 52.3% year over year to $373.8 million during the first half of 2025.
Halozyme is gearing up to report its third-quarter results on Nov. 3.
Management expects total revenues in the second half of 2025 to be driven by continued strong growth of J&J’s Darzalex SC, Roche’s Phesgo and argenx’s Vyvgart Hytrulo. Our model estimates Halozyme's revenues from royalties to increase at a CAGR of 23.2% over the next three years.
Halozyme has two commercial proprietary products, Hylenex and Xyosted, with the latter acquired from Antares Pharma in 2022. Incremental sales from these products also boosted Halozyme’s revenues during the first half of 2025.
For 2025, Halozyme projects total revenues in the range of $1.28 billion to $1.36 billion. Royalty revenues are anticipated in the range of $825-$860 million.
HALO's Price Performance, Valuation and Estimates
Year to date, shares of Halozyme have rallied 37.6% compared with the industry’s rise of 10.5%. The stock has also outperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Halozyme is trading at a premium to the industry. Going by the price-to-sales (P/S) ratio, the company’s shares currently trade at 6.93, higher than 2.28 for the industry. The stock is trading below its five-year mean of 8.43.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share (EPS) has increased from $6.01 to $6.17 over the past 60 days. During the same time frame, EPS estimates for 2026 have moved up from $7.48 to $7.62.
Image: Bigstock
Will Higher Royalties From Partners Fuel HALO's Growth in H2 2025?
Key Takeaways
Halozyme Therapeutics (HALO - Free Report) has collaboration agreements with large pharma companies, which use its ENHANZE technology for the development of subcutaneous (SC) formulations of their various approved drugs. Halozyme now has eight marketed partnered drugs based on this technology, including the subcutaneous formulation of J&J’s (JNJ - Free Report) Darzalex and Roche’s (RHHBY - Free Report) Phesgo.
Per the agreements, these companies have been granted worldwide license rights to develop and commercialize their products using ENHANZE technology. These deals generate royalties on sales of marketed drugs, milestone payments and annual license fees, which comprise Halozyme’s top line.
Halozyme’s top line also comprises product sales, royalty payments from Roche for Phesgo and J&J for SC Darzalex as well as revenues under collaboration agreements related to its Enhanze technology with some large pharma companies. Total revenues in the first half of 2025 were driven by higher royalty payments from Roche for Phesgo and J&J for SC Darzalex (daratumumab), as well as argenx’s Vyvgart Hytrulo. Revenues from royalties rose 52.3% year over year to $373.8 million during the first half of 2025.
Halozyme is gearing up to report its third-quarter results on Nov. 3.
Management expects total revenues in the second half of 2025 to be driven by continued strong growth of J&J’s Darzalex SC, Roche’s Phesgo and argenx’s Vyvgart Hytrulo. Our model estimates Halozyme's revenues from royalties to increase at a CAGR of 23.2% over the next three years.
Halozyme has two commercial proprietary products, Hylenex and Xyosted, with the latter acquired from Antares Pharma in 2022. Incremental sales from these products also boosted Halozyme’s revenues during the first half of 2025.
For 2025, Halozyme projects total revenues in the range of $1.28 billion to $1.36 billion. Royalty revenues are anticipated in the range of $825-$860 million.
HALO's Price Performance, Valuation and Estimates
Year to date, shares of Halozyme have rallied 37.6% compared with the industry’s rise of 10.5%. The stock has also outperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Halozyme is trading at a premium to the industry. Going by the price-to-sales (P/S) ratio, the company’s shares currently trade at 6.93, higher than 2.28 for the industry. The stock is trading below its five-year mean of 8.43.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share (EPS) has increased from $6.01 to $6.17 over the past 60 days. During the same time frame, EPS estimates for 2026 have moved up from $7.48 to $7.62.
Image Source: Zacks Investment Research
HALO's Zacks Rank
Halozyme currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.